科望医药ESMO Asia口头报告公布全球首创ES014单药疗法Ⅰ期亮眼数据

Core Insights - The article discusses the Phase I clinical trial results of ES014, a bispecific antibody developed by Kewang Pharmaceutical, presented at the ESMO Asia conference on December 5, 2025. [1] - ES014 is the world's first CD39/TGFβ bispecific antibody to enter clinical trials, showing promising anti-tumor activity in various cancer types with high unmet clinical needs. [1] Clinical Trial Results - In the treatment of desmoplastic tumors (DT), ES014 achieved an overall response rate (ORR) of 40% and a disease control rate (DCR) of 100%, indicating significant potential as an innovative treatment option. [1] - For non-small cell lung cancer (NSCLC), ES014 demonstrated preliminary efficacy in patients with high CD39 expression, laying the groundwork for precision medicine strategies. [1] - ES014 may provide a new treatment option for wild-type gastrointestinal stromal tumor (GIST) patients, who have very limited clinical treatment choices. [1] Strategic Implications - As ES014 and other core pipelines show initial clinical benefits, Kewang Pharmaceutical's value realization is expected to increase, particularly with its unique myeloid cell connector (MCE) platform. [1] - The company is focused on immunology and original research innovation, which may enhance its potential for international licensing and collaboration opportunities. [1] - From a long-term perspective in the innovative drug industry, once the clinical value of the innovative pipeline is recognized internationally, the sustainability of cash flow is likely to shift from being "financing-driven" to "transaction and collaboration-driven." [1]